Formulations of Cannabidiol Derivatives and Their Use as Modulators of Cannabinoid Receptor Type 2 (CB2)
AssigneeEmerald Health Pharmaceuticals Inc
InventorsAlain ROLLAND, Eduardo Munoz BLANCO
Life of this patent
Estimating the term…
Abstract
Compositions, comprising the cannabidiol derivatives of Formula (I) in pharmaceutical formulations displaying increased bioavailability and solubility are described. Cannabidiol derivatives of Formula (I) and compositions comprising the same for use in the treatment of various conditions, and diseases, including diseases associated with demyelination.
Claims53
A composition comprising at least one compound of Formula (I), or a derivative thereof.
- wherein R is the nitrogen atom of a group independently selected from a linear or branched alkylamine, an aryl amine, an arylalkylamine, a heteroarylamine, a heteroarylalkylamine, a linear or branched alkenylamine, a linear or branched alkynylamine, or NH2,
- in a pharmaceutical vehicle,
- wherein the pharmaceutical vehicle is selected from the group consisting of aqueous buffers, solvents, co-solvents, cyclodextrin complexes, lipid vehicles, and any combination thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A liquid formulation, comprising compound of Formula (VIII), or a derivative thereof, in a pharmaceutical vehicle, wherein the pharmaceutical vehicle is 50:50 v/v Maisine CC:maize oil mixture.
A method of treating a multiple sclerosis or systemic sclerosis in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of the compound of Formula (VIII) or a formulation thereof, or a derivative thereof,
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.